A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Recruiting

I'm Interested

Trial ID: NCT01732822

Age - 50 Years-130 Years Condition - Peripheral Artery Disease Gender - All Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Official Title

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Eligibility


Inclusion Criteria:

   - Male and Female patients 50 years old or older Symptomatic peripheral artery disease

Exclusion Criteria:

   - Patients needing dual anti-platlet drug treatment before start of study Planned
   revascularisation or amputation

   - Patients with known bleeding disorders

   - Patients with a history of intracranial bleed

   - Patients considered to be at risk of bradycardic events unless already treated with a
   permanent pacemaker

View More
View Less

Intervention(s):

drug: Ticagrelor

drug: Clopidogrel

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
AstraZeneca Clinical Study Information
800-236-9933

©2024 Stanford Medicine